Vascular stent capable of promoting vascular cell proliferation and secreting extracellular matrix, preparation method of vascular stent and active artificial blood vessel

A vascular stent and vascular cell technology, applied in the field of active artificial blood vessels, can solve the problems of limited ability of passage growth and secretion of extracellular matrix, reduced cell growth and vitality, bacterial contamination, etc., to reduce the risk of infection and improve compatibility. Sex, improve activity effect

Active Publication Date: 2020-09-29
领博生物科技(杭州)有限公司
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, these tissue engineering techniques all use simple polymer vascular scaffolds without any functional modification or addition of drugs, except for mechanical stimulation, without any intervention on cell proliferation and secretion. Therefore, in vitro bioreactor culture Process takes more than 8 weeks
The longer the process, the higher

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vascular stent capable of promoting vascular cell proliferation and secreting extracellular matrix, preparation method of vascular stent and active artificial blood vessel
  • Vascular stent capable of promoting vascular cell proliferation and secreting extracellular matrix, preparation method of vascular stent and active artificial blood vessel
  • Vascular stent capable of promoting vascular cell proliferation and secreting extracellular matrix, preparation method of vascular stent and active artificial blood vessel

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] A PCL vascular stent capable of promoting vascular cell proliferation and secreting extracellular matrix modified by IGF-1 polypeptide self-assembly, the preparation method comprising the following steps:

[0048] 1. Bracket processing:

[0049] (1) The inner layer of the stent was prepared by melt spinning, and the specific operation steps were as follows: Weigh 5.0 g of PCL with a molecular weight of 80,000, place it in a closed stainless steel syringe wrapped in a fuser, and heat it at 100°C for 1 hour; A stainless steel tube (receiving rod) with a diameter of 2mm is connected to the rotating motor, the distance between the syringe needle and the receiving rod is 5mm, the flow rate of the PCL melt is 0.5mL / h, the rotating speed of the receiving rod is 300r / min, and the translation speed of the receiver is 10mm / s, the spinning time is 5min, the prepared fiber angle is 50°, the fiber diameter is 60μm, and the inner layer fiber with wall thickness is 300μm;

[0050] (2...

Embodiment 2

[0074] A PCL / collagen composite vascular stent capable of promoting vascular cell proliferation and secreting extracellular matrix for slow release of IGF-1 polypeptide, the preparation method comprising the following steps:

[0075] First, the PCL / collagen composite stent was prepared by electrospinning technology. PCL was dissolved in a mixed solvent of chloroform and methanol (5:1 by volume) at a concentration of 10% (w / v). Type I collagen was dissolved in hexafluoroisopropanol at a concentration of 8% (w / v). IGF-1 polypeptide was dissolved in deionized water at a concentration of 2mg / mL. Add the IGF-1 polypeptide solution to the collagen solution, the volume ratio is 4:1, and mix well.

[0076] Fill the PCL solution and collagen / IGF-1 solution into two 10-mL syringes with 21-G needles, respectively. The two syringes are respectively installed on the two syringe pumps, and the rotating receiving rod is a stainless steel tube with a diameter of 2-6mm. The distance betwee...

Embodiment 3

[0083] A VEGF growth factor modified PCL / gelatin composite vascular stent capable of promoting vascular cell proliferation and secreting extracellular matrix, the preparation method comprising the following steps:

[0084] Firstly, the PCL / gelatin composite vascular stent was prepared by electrospinning technology. PCL was dissolved in a mixed solvent of chloroform and methanol (5:1 by volume) at a concentration of 25% (w / v). A gelatin solution was then prepared by dissolving gelatin in hexafluoroisopropanol at a concentration of 6% (w / v). Add the two solutions into two 10mL syringes, use 21G needles, and install them on two syringe pumps respectively. The high-voltage power supplies connected to the two syringes of PCL and gelatin are respectively, PCL11kV, and gelatin 17kV. The distances between the needles of the two syringes and the receiving rods are 25 cm for PCL and 15 cm for gelatin. The two materials were spun simultaneously to prepare the PCL / gelatin composite vasc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fiber diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of tissue engineering, and particularly relates to a vascular stent capable of promoting vascular cell proliferation and secreting extracellular matrix. The vascular stent is characterized by comprising a tubular polymer fiber stent added with active factors, wherein the active factors comprise at least one of IGF-1, VEGF, PDGF and bFGF growth factors,and/or at least one of polypeptides corresponding to IGF-1, VEGF, PDGF and bFGF growth factors, and/or at least one of RGD short peptides and NO donor molecules; and the tubular polymer fiber stent ismade of degradable polymer materials. The vascular stent has the beneficial effects that according to the vascular stent modified by active and functions, in the process of constructing an extracellular matrix artificial blood vessel in vitro tissue engineering, the proliferation rate of cells and the rate of secreting the extracellular matrix can be remarkably increased, and the in vitro cell culture time is greatly shortened; and in addition, the tissue regeneration activity of the vascular material is also remarkably improved, and the requirement of clinical treatment is met.

Description

technical field [0001] The invention belongs to the technical field of tissue engineering, and in particular relates to a blood vessel support capable of promoting proliferation of blood vessel cells and secreting extracellular matrix, a preparation method of the blood vessel support and an active artificial blood vessel. Background technique [0002] Vascular disease is the disease with the highest fatality rate in the world. The occurrence of this disease is often due to the reduction of blood flow and lack of nutrients caused by vascular stenosis or obstruction, which damages tissues or organs. It usually manifests as coronary heart disease, cerebrovascular disease, peripheral arterial disease. According to the prediction of the World Health Organization, by 2030, the number of people dying of cardiovascular-related diseases in the world will increase to 23.3 million each year. Vascular grafting is still a routine method for the treatment of such diseases, and the use of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L31/04A61L31/06A61L31/00A61L31/14A61L31/16A61L31/12A61L27/40A61L27/22A61L27/18A61L27/24A61L27/36A61L27/38A61L27/50A61L27/54A61L27/56A61L27/58
CPCA61L31/047A61L31/06A61L31/045A61L31/044A61L31/005A61L31/14A61L31/146A61L31/16A61L31/148A61L27/227A61L27/18A61L27/222A61L27/24A61L27/3633A61L27/3687A61L27/3691A61L27/3808A61L27/3826A61L27/507A61L27/50A61L27/54A61L27/56A61L27/58A61L2300/414A61L2300/252A61L2430/40C08L89/00C08L67/04
Inventor 张杰王恺万烨
Owner 领博生物科技(杭州)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap